Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys
| dc.contributor.author | Blanchet, P. J. | en |
| dc.contributor.author | Konitsiotis, S. | en |
| dc.contributor.author | Chase, T. N. | en |
| dc.date.accessioned | 2015-11-24T19:36:49Z | |
| dc.date.available | 2015-11-24T19:36:49Z | |
| dc.identifier.issn | 0885-3185 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/23946 | |
| dc.rights | Default Licence | - |
| dc.subject | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | en |
| dc.subject | Amantadine/*administration & dosage/adverse effects | en |
| dc.subject | Animals | en |
| dc.subject | Antiparkinson Agents/administration & dosage/*adverse effects | en |
| dc.subject | Dopamine Agents/*administration & dosage/adverse effects | en |
| dc.subject | Dose-Response Relationship, Drug | en |
| dc.subject | Dyskinesia, Drug-Induced/*drug therapy/physiopathology | en |
| dc.subject | Injections, Subcutaneous | en |
| dc.subject | Levodopa/administration & dosage/*adverse effects | en |
| dc.subject | Macaca fascicularis | en |
| dc.subject | Neurologic Examination/drug effects | en |
| dc.subject | Parkinson Disease, Secondary/chemically induced/*drug therapy/physiopathology | en |
| dc.subject | Receptors, N-Methyl-D-Aspartate/drug effects/physiology | en |
| dc.title | Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys | en |
| heal.abstract | The antidyskinetic potential of the glutamate NMDA receptor channel blocker amantadine was evaluated in four levodopa-primed parkinsonian monkeys using two different regimens (1.25 or 2.5 mg/kg administered subcutaneously twice daily for 3-6 days). When administered with a relatively low dose of levodopa, amantadine produced a near-total suppression of choreiform dyskinesias and a substantial reduction in dystonic dyskinesias at the expense of a significant reduction in antiparkinsonian response. With a high dose of levodopa, amantadine had a smaller but still significant effect on dyskinesias without altering the antiparkinsonian response. These results lend support to the view that glutamate receptor-mediated mechanisms contribute to levodopa-induced dyskinesias. They also suggest that amantadine could alleviate such complications in parkinsonian patients, especially with careful dose optimization. | en |
| heal.access | campus | - |
| heal.fullTextAvailability | TRUE | - |
| heal.identifier.primary | 10.1002/mds.870130507 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/9756148 | - |
| heal.identifier.secondary | http://onlinelibrary.wiley.com/store/10.1002/mds.870130507/asset/870130507_ftp.pdf?v=1&t=h0aqonvp&s=ac78282c5387f307d47df9cc9928fd8c42927914 | - |
| heal.journalName | Mov Disord | en |
| heal.journalType | peer-reviewed | - |
| heal.language | en | - |
| heal.publicationDate | 1998 | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.type | journalArticle | - |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.type.en | Journal article | en |
Αρχεία
Φάκελος/Πακέτο αδειών
1 - 1 of 1
Φόρτωση...
- Ονομα:
- license.txt
- Μέγεθος:
- 1.74 KB
- Μορφότυπο:
- Item-specific license agreed upon to submission
- Περιγραφή: